Clinical trial
A Two-part, Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered COR-2003, as Monotherapy (Part A) and Co-administered With COR-1004 (Part B)
NCT07858019 is registered in ClinicalTrials.gov with Corsera Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-part, Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered COR-2003, as Monotherapy (Part A) and Co-administered With COR-1004 (Part B)
- Lead sponsor
- Corsera Health
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- May 31, 2028
- Enrollment
- 108 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
otherwise healthy individuals with systolic blood pressure (sbp) from 110 to 139 mmhg and low-density lipoprotein cholesterol (ldl-c) ≥ 100 mg/dl